Tus kws kho mob
QP63-22 MHCP Pharmacy Benefit Update – New drug-related Prior Authorization (PA) with Quantity Limit (QL) Criteria: Ryplazim® (plasminogen, human-tvmh)
Hnub Tim pib siv tau lub khoos kas: Lub Xya Hli Ntuj Tim 27, 2022
Tshawb Nrhiav
Nthuav pom cov txiaj ntsig tshwm sim 1731 - 1740 ntawm 3685
Tus kws kho mob
P44-22 New Medical, Medical Drug and Behavioral Health Policy Management Updates: Effective October 3, 2022
Hnub Tim pib siv tau lub khoos kas: Lub Yim Hlis Ntuj Tim 01, 2022
Tus kws kho mob
P45-22 Medical Policy Updates: Coupe Health and Self-Funded Benefit Plans managed by Blue Cross and Blue Shield of Alabama
Hnub Tim pib siv tau lub khoos kas: Lub Yim Hlis Ntuj Tim 01, 2022
Tus kws kho mob
QP61-22 Free Continuing Education for Mental Health Providers through 12/31/22
Hnub Tim pib siv tau lub khoos kas: Lub Xya Hli Ntuj Tim 27, 2022
Tus kws kho mob
upcoming-policies-effective-september-5_-2022.pdf
Tus kws kho mob
QP47-22 Medical Drug Management Update – Alpha-1 Proteinase Inhibitors
Hnub Tim pib siv tau ntawm lub khoos kas: Rau Hlis Ntuj Tim 08, 2022
Tus kws kho mob
QP48-22 MHCP Pharmacy Benefit Exclusion for Korsuva™ and Leqvio®
Hnub Tim pib siv tau ntawm lub khoos kas: Rau Hlis Ntuj Tim 08, 2022
Tus kws kho mob
QP49-22 Commercial Pharmacy Benefit Exclusion for Carvykti™, Korsuva™, and Leqvio®
Hnub Tim pib siv tau ntawm lub khoos kas: Rau Hlis Ntuj Tim 08, 2022
Tus kws kho mob
QP50-22 Commercial Pharmacy Benefit Update: Revised Drug-Related Prior Authorization (PA) Requirement Notification, Effective August 1, 2022
Hnub Tim pib siv tau ntawm lub khoos kas: Rau Hlis Ntuj Tim 08, 2022
Tus kws kho mob
P42-22 Mental Health and Substance Use Disorder Provider Survey
Hnub Tim pib siv tau lub khoos kas: Lub Xya Hli Ntuj Tim 01, 2022